Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial

• Главные авторы: Bastiaan T. van Dijk (Автор), Sytske Anne Bergstra (Автор), J. Merlijn van den Berg (Автор), Dieneke Schonenberg-Meinema (Автор), Lisette W.A. van Suijlekom-Smit (Автор), Marion A.J. van Rossum (Автор), Yvonne Koopman-Keemink (Автор), Rebecca ten Cate (Автор), Cornelia F. Allaart (Автор), Daniëlle M.C. Brinkman (Автор), Petra C.E. Hissink Muller (Автор)
• Формат: ‌
• Опубликовано: BMC, 2024-05-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Background Etanercept has been studied in doses up to 0.8 mg/kg/week (max 50 mg/week) in juvenile idiopathic arthritis (JIA) patients. In clinical practice higher doses are used off-label, but evidence regarding the relation with outcomes is lacking. We describe the clinical course of JIA-p...